Edesa Biotech, Inc. 8-K

What Happened

• Edesa Biotech, Inc. (EDSA) announced its financial results for the three- and six-month periods ended March 31, 2026 via a press release dated May 14, 2026. The company furnished the press release as Exhibit 99.1 to its Form 8-K filed May 14, 2026. The 8-K was signed by CFO Peter J. Weiler.

Key Details

• Date of filing: May 14, 2026.
• Reporting period: Three and six months ended March 31, 2026.
• Exhibit: Press release attached as Exhibit 99.1 (the text of the earnings/financial results).
• Regulatory note: The information furnished is not “filed” under Section 18 of the Exchange Act and is not automatically incorporated by reference.

Why It Matters

• This filing provides retail investors with the company’s latest earnings and quarterly results for the periods ending March 31, 2026. The attached press release is the primary source for revenue, net income (or loss), cash flow and other performance metrics; investors should review that release for specifics.
• Because the release is furnished (not filed), it carries more limited legal liability and is not automatically incorporated into other SEC filings, but it is still the company’s official public report of recent financial performance.